News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
422,986 Results
Type
Article (18460)
Company Profile (122)
Press Release (404394)
Multimedia
Podcasts (81)
Webinars (14)
Section
Business (136213)
Career Advice (872)
Deals (24745)
Drug Delivery (83)
Drug Development (47926)
Employer Resources (71)
FDA (8802)
Job Trends (8682)
News (221711)
Policy (18833)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (705)
Accelerated approval (20)
Adcomms (12)
Allergies (97)
Alliances (31538)
ALS (90)
Alzheimer's disease (726)
Antibody-drug conjugate (ADC) (165)
Approvals (9093)
Artificial intelligence (306)
Autoimmune disease (104)
Automation (21)
Bankruptcy (213)
Best Places to Work (6157)
BIOSECURE Act (10)
Biosimilars (150)
Biotechnology (56)
Bladder cancer (81)
Brain cancer (38)
Breast cancer (265)
Cancer (2256)
Cardiovascular disease (234)
Career advice (763)
Career pathing (18)
CAR-T (112)
CDC (9)
Cell therapy (313)
Cervical cancer (18)
Clinical research (41868)
Collaboration (1074)
Compensation (664)
Complete response letters (45)
COVID-19 (1011)
CRISPR (59)
C-suite (741)
Cystic fibrosis (77)
Data (3205)
Decentralized trials (1)
Denatured (19)
Depression (68)
Dermatology (25)
Diabetes (219)
Diagnostics (3097)
Digital health (20)
Diversity (4)
Diversity, equity & inclusion (20)
Drug discovery (156)
Drug pricing (140)
Drug shortages (15)
Duchenne muscular dystrophy (124)
Earnings (61352)
Editorial (31)
Employer branding (13)
Employer resources (68)
Events (66353)
Executive appointments (796)
FDA (10504)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (8)
Frontotemporal dementia (13)
Funding (768)
Gene editing (96)
Generative AI (28)
Gene therapy (292)
GLP-1 (567)
Government (1771)
Grass and pollen (4)
Guidances (271)
Healthcare (7525)
HIV (25)
Huntington's disease (19)
IgA nephropathy (51)
Immunology and inflammation (127)
Immuno-oncology (31)
Indications (93)
Infectious disease (1120)
Inflammatory bowel disease (104)
Inflation Reduction Act (7)
Influenza (38)
Intellectual property (144)
Interviews (110)
IPO (11119)
IRA (38)
Job creations (2751)
Job search strategy (684)
JPM (35)
Kidney cancer (14)
Labor market (37)
Layoffs (301)
Leadership (16)
Legal (5091)
Liver cancer (42)
Longevity (10)
Lung cancer (296)
Lymphoma (194)
Machine learning (19)
Management (23)
Manufacturing (580)
MASH (111)
Medical device (4802)
Medtech (4825)
Mergers & acquisitions (14354)
Metabolic disorders (689)
mRNA (67)
Multiple sclerosis (68)
NASH (18)
Neurodegenerative disease (142)
Neuropsychiatric disorders (52)
Neuroscience (1379)
Neurotech (1)
NextGen: Class of 2026 (2869)
Non-profit (1203)
Now hiring (26)
Obesity (334)
Opinion (184)
Ovarian cancer (63)
Pain (137)
Pancreatic cancer (94)
Parkinson's disease (135)
Partnered (16)
Patents (282)
Patient recruitment (225)
Peanut (22)
People (42393)
Pharmaceutical (62)
Pharmacy benefit managers (19)
Phase 1 (11599)
Phase 2 (17960)
Phase 3 (15305)
Pipeline (4311)
Policy (167)
Postmarket research (1729)
Preclinical (4671)
Press Release (72)
Prostate cancer (128)
Psychedelics (21)
Radiopharmaceuticals (217)
Rare diseases (554)
Real estate (3816)
Recruiting (28)
Regulatory (14440)
Reports (24)
Research institute (808)
Resumes & cover letters (128)
Rett syndrome (28)
RNA editing (9)
RSV (24)
Schizophrenia (108)
Series A (138)
Series B (105)
Service/supplier (2)
Sickle cell disease (57)
Special edition (13)
Spinal muscular atrophy (127)
Sponsored (17)
Startups (2246)
State (2)
Stomach cancer (8)
Supply chain (66)
Tariffs (76)
The Weekly (60)
Vaccines (335)
Venture capital (52)
Weight loss (190)
Women's health (47)
Worklife (5)
Date
Today (43)
Last 7 days (253)
Last 30 days (1371)
Last 365 days (16127)
2026 (4553)
2025 (16503)
2024 (19559)
2023 (22809)
2022 (31096)
2021 (32578)
2020 (30638)
2019 (23683)
2018 (18364)
2017 (19761)
2016 (18575)
2015 (22496)
2014 (18492)
2013 (15579)
2012 (16767)
2011 (17457)
2010 (16480)
Location
Africa (447)
Alabama (36)
Alaska (3)
Arizona (123)
Arkansas (5)
Asia (27540)
Australia (3659)
California (6193)
Canada (2163)
China (746)
Colorado (293)
Connecticut (284)
Delaware (183)
Europe (56293)
Florida (1084)
Georgia (132)
Hawaii (1)
Idaho (29)
Illinois (512)
India (69)
Indiana (324)
Iowa (11)
Japan (362)
Kansas (93)
Kentucky (31)
Louisiana (17)
Maine (56)
Maryland (662)
Massachusetts (4893)
Michigan (140)
Minnesota (320)
Mississippi (2)
Missouri (64)
Montana (19)
Nebraska (15)
Nevada (64)
New Hampshire (25)
New Jersey (2172)
New Mexico (11)
New York (1635)
North Carolina (952)
North Dakota (5)
Northern California (3055)
Ohio (196)
Oklahoma (7)
Oregon (22)
Pennsylvania (1217)
Puerto Rico (18)
Rhode Island (26)
South America (676)
South Carolina (26)
Southern California (2516)
Tennessee (114)
Texas (941)
United States (23062)
Utah (159)
Virginia (232)
Washington D.C. (46)
Washington State (479)
West Virginia (3)
Wisconsin (77)
Wyoming (1)
422,986 Results for "novartis pharmaceuticals corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Novartis Keeps Deals Coming With $2B Excellergy Takeover
The Excellergy acquisition will complement Novartis’ existing allergy profile, anchored by the IgE blocker Xolair that in February 2024 was approved to treat food allergies in children and adults.
March 27, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Novartis Pledges $480M To Expand China Presence, Following Eli Lilly and AstraZeneca
Like its pharma peers, Novartis is pouring money into Chinese operations, including expansions and upgrades at an existing manufacturing facility.
March 24, 2026
·
2 min read
·
Nick Paul Taylor
Breast cancer
Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals
Aside from the $2 billion upfront payment, Novartis is also putting up to $1 billion on the line in milestones for Synnovation Therapeutics’ pan-mutant-selective PI3Kα blocker.
March 20, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Novartis Names Texas City as Location of Its 5th US Radiopharmaceutical Facility
The Denton site is part of a network of manufacturing plants Novartis is building across the U.S. to make cancer drugs that must be shipped to patients quickly.
February 25, 2026
·
2 min read
·
Nick Paul Taylor
Collaboration
Novartis Bets Up to $1.7B in Cardio-Focused Peptide Partnership
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
February 19, 2026
·
2 min read
·
Tristan Manalac
Pipeline
Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy
Despite the Phase 1 cull, CEO Vas Narasimhan on Wednesday maintained that Novartis continues to invest in its early-stage pipeline, looking for deals in the “sub-$2-billion range.”
February 5, 2026
·
2 min read
·
Tristan Manalac
Earnings
Novartis Sticks With M&A Strategy of Building Early Pipeline, Searching for Near-Launches
Novartis will still be on the lookout for early-stage deals under $2 billion, and later-stage agreements around a product that could reach the market within five years, CEO Vas Narasimhan said Wednesday.
February 4, 2026
·
2 min read
·
Tristan Manalac
Funding
Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors
Sidewinder Therapeutics’ bispecific antibody-drug conjugates target pairs of receptors found on cancer cells, which the company claims improves their specificity and minimizes off-target effects.
April 9, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Novartis Makes $1.5B+ Alzheimer’s Play With China’s SciNeuro
The deal will see Novartis gain global rights over SciNeuro’s potentially disease-modifying anti-amyloid antibody, which leverages the latter’s proprietary shuttle platform to allow delivery into the brain.
January 12, 2026
·
2 min read
·
Tristan Manalac
Layoffs
Voyager Throws 30 Staff Overboard After Novartis Sinks Two Programs
Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last month. Projects under the deal for spinal muscular atrophy and Huntington’s disease continue to advance.
December 18, 2025
·
2 min read
·
Tristan Manalac
1 of 42,299
Next
